Skip to main content
Clinical Trials/NCT02713113
NCT02713113
Completed
Phase 3

Comparison of Three Different Doses Sugammadex Based on Ideal Body Weight for Reversal of Moderate Rocuronium-induced Neuromuscular Blockade in Laparoscopic Bariatric Surgery.

Assiut University1 site in 1 country180 target enrollmentStarted: March 2015Last updated:

Overview

Phase
Phase 3
Status
Completed
Enrollment
180
Locations
1
Primary Endpoint
sugammadex time following a dose of 1.5 mg / kg of sugammadex according to IBW in comparison to 2, and 4 mg / kg,

Overview

Brief Summary

the investigators aimed to compare the efficacy and safety of sugammadex at doses of 1.5, 2, and 4 mg/ kg for the reversal of moderate rocuronium-induced neuromuscular blockade in laparoscopic bariatric surgery.

Detailed Description

Patients were randomly assigned using a randomization-computer program into three groups according to the dose of sugammadex administrated (according to the IBW after T2 of TOF):

Group I: patients were given 1.5 mg / kg. Group II: patients were given 2 mg / kg. Group III: patients were given 4 mg / kg.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Health Services Research
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • morbidly obese patients of both sex (BMI \> 40 kg.m-2)
  • scheduled for elective laparoscopic bariatric surgery (gastric bypass or sleeve surgery) under general anesthesia using rocuronium for tracheal intubation and maintenance of NMB
  • aged between 18 and 60 years and classified as ASA II - III

Exclusion Criteria

  • liver and renal dysfunction,
  • disabling neuropsychiatric disorders,
  • history of stroke, brain trauma in the last 12 months
  • hypersensitivity to anesthetics, history of myocardial infarction, congestive heart failure
  • difficult tracheal intubation, and known or suspected disorder affecting NMB.

Arms & Interventions

group 1

Active Comparator

patients were given 1.5 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)

Intervention: sugammadex reversal of neuromuscular blockade (Drug)

group II

Active Comparator

patients were given 2 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)

Intervention: sugammadex reversal of neuromuscular blockade (Drug)

group III

Active Comparator

patients were given 4 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)

Intervention: sugammadex reversal of neuromuscular blockade (Drug)

Outcomes

Primary Outcomes

sugammadex time following a dose of 1.5 mg / kg of sugammadex according to IBW in comparison to 2, and 4 mg / kg,

Time Frame: 2 hrs

Secondary Outcomes

  • extubation time(2 hrs)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Fatma Adel El sherif

principal investigator

Assiut University

Study Sites (1)

Loading locations...

Similar Trials